Aurora-A在胰腺癌的表达及与吉西他滨耐药的相关性研究

目的探讨Aurora—A的表达与胰腺癌吉西他滨耐药的相关性。方法qPCR法测定PANC-1和耐药细胞株PANC．1／R2中Aurora-A mRNA的表达；分别用PANC．1和PANC．1／R2建立胰腺癌动物模型，免疫组化方法测定瘤体Aurora-A的表达。结果PANC-1组模型第5周肿瘤转移率36．8％（7／19），裸鼠体重（23．2±1．41）g，肿瘤重量（0．453±0．110）g；PANC-1／R2组模型第5周肿瘤转移率50％（9／18），裸鼠体重（22．91±1．13）g，肿瘤重量（0．564±0．203）g。转移率和肿瘤质量两组比较差异有统计学意义。PANC-1组Aurora-AmRNA表达为（1．002±0．040）；PANC—1／R2组Aurora-A mRNA表达为（1．845±0．069），两组比较差异有统计学意义（P〈0．05）。PANC-1／R2组18例标本组织中Aurora—A蛋白阳性表达15例（83.3％）；PANC-1组19例组织的Aurora—A蛋白检测阳性表达11例（57．9％），两组比较差异有统计学意义（P〈0．05）。结论Aurora-A基因高表达与胰腺癌细胞株的吉西他滨耐药有关，新方法构建的PANC-1／R2耐药株Aurora-A基因高表达，可用于胰腺癌吉西他滨耐药研究的载体。

Objective To assess the relationship of Aurora-A expression with gemcitabine-resistance of pancreatic cancer. Methods The expression ofAurora-A mRNA of PANC-1 and PANC-1/R2 cells were tested by qPCR technique. The animal models of pancreatic cancer were estblised by PANC-1 and PANC-1/R2 cells. After 35days, mice were killed, and the tumor tissues were collected. The Aurora-A protein expression of the two groups were deteched by Immunohistochemistry. Results In the PANC-1 group, the metastasis of tumor on the five weeks was 36.8% （ 7/19 ） , the mean weight of tumor tissues was 0.453 ± 0,110 g, and weight of mice was 23.2 ± 1.41 g. While the metastasis of tumor on the five weeks was 50% （ 9/18 ） , the mean weight of tumor tissues was 0.564 ±0.203g, and weight of mice was 22.91 ± 1.13g in PANC-1/R2 group. The metastatic rate and weight of tumor were with significant differences （ P〈0.05 ） . The expression ofAurora-A mRNA of PANC-1 cells was 1.002 ± 0.040; while it was 1.845 ± 0.069 in PANC-1/R2, it was significant difference between the two groups （P〈0.05 ） . A 15 of 18 cases positive expression of Aurora-A protein were detected in PANC-1/R2 group, while it was 11 of 19 cases in PANC-1 group. The significant difference was found between the two groups （ P〈0.05 ） . Conclusions High expression ofAurora-A gene is associated with gemcitabine- resistance of pancreatic cancer cell lines. PANC-1/R2 cell was suocessful as a cell model of gemcitabine-resistance of pancreatic cancer.